D. Boral Capital Begins Coverage on Context Therapeutics (NASDAQ:CNTX)

Stock analysts at D. Boral Capital began coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a research note issued on Monday, Marketbeat reports. The brokerage set a “buy” rating and a $9.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Context Therapeutics in a research note on Monday, September 23rd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Context Therapeutics has an average rating of “Buy” and an average target price of $6.80.

Context Therapeutics Stock Performance

NASDAQ CNTX opened at $1.47 on Monday. The stock has a market capitalization of $110.25 million, a P/E ratio of -1.62 and a beta of 2.25. Context Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.75. The stock has a fifty day moving average of $1.97 and a 200-day moving average of $2.08.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). Equities research analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CNTX. Driehaus Capital Management LLC acquired a new stake in shares of Context Therapeutics in the second quarter valued at approximately $4,527,000. Great Point Partners LLC acquired a new stake in Context Therapeutics in the 2nd quarter valued at $14,876,000. Blue Owl Capital Holdings LP bought a new stake in Context Therapeutics during the 2nd quarter worth about $10,348,000. Nantahala Capital Management LLC acquired a new position in shares of Context Therapeutics during the 2nd quarter worth about $3,881,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after acquiring an additional 25,300 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.